Could brenipatide reduce alcohol cravings, and what are the trials actually measuring?

That is a serious research question, but brenipatide’s benefit should not be assumed. RENEW-ALC-1 and RENEW-ALC-2 compare it with placebo in adults with alcohol use disorder, with each trial targeting about 1,100 participants. The programs examine changes in drinking patterns, including assessment through the Timeline Followback method, which records drinking over time. Lower craving, fewer heavy-drinking days and sustained abstinence are different outcomes. A useful result needs to show what changed versus placebo, how much it changed and whether participants remained in treatment.[1][2]

There is a clinical rationale from related research: a small randomized semaglutide trial reported reductions in laboratory alcohol consumption and some craving and drinking measures. That was semaglutide, not brenipatide, and it does not establish a class-wide cure for addiction. The reviewed RENEW-ALC-1 record has no posted results, so a numerical brenipatide success rate would be premature. When results arrive, placebo-adjusted drinking outcomes, adverse events, discontinuations and the durability of benefit will matter more than a general headline about “turning off cravings.”[1][3]